Kågedal B - Search Results

1

ppGalNAc-T13: a new molecular marker of bone marrow involvement in neuroblastoma.

Berois N, Blanc E, Ripoche H, Mergui X, Trajtenberg F, Cantais S, Barrois M, Dessen P, Kågedal B, Bénard J, Osinaga E, Raguénez G. Berois N, et al. Among authors: kagedal b. Clin Chem. 2006 Sep;52(9):1701-12. doi: 10.1373/clinchem.2006.067975. Epub 2006 Jul 27. Clin Chem. 2006. PMID: 16873292

2

Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastoma cells in blood and bone marrow.

Träger C, Kogner P, Lindskog M, Ponthan F, Kullman A, Kågedal B. Träger C, et al. Among authors: kagedal b. Clin Chem. 2003 Jan;49(1):104-12. doi: 10.1373/49.1.104. Clin Chem. 2003. PMID: 12507966 Clinical Trial.

3

Detecting minimal residual disease in neuroblastoma: still a ways to go.

Kågedal B. Kågedal B. Clin Chem. 2009 Jul;55(7):1268-70. doi: 10.1373/clinchem.2009.127308. Epub 2009 May 14. Clin Chem. 2009. PMID: 19443561 No abstract available.

4

mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.

Träger C, Vernby A, Kullman A, Ora I, Kogner P, Kågedal B. Träger C, et al. Among authors: kagedal b. Int J Cancer. 2008 Dec 15;123(12):2849-55. doi: 10.1002/ijc.23846. Int J Cancer. 2008. PMID: 18814238

5

Failure of the PAXgene Blood RNA System to maintain mRNA stability in whole blood.

Kågedal B, Lindqvist M, Farnebäck M, Lenner L, Peterson C. Kågedal B, et al. Clin Chem Lab Med. 2005;43(11):1190-2. doi: 10.1515/CCLM.2005.206. Clin Chem Lab Med. 2005. PMID: 16232084

6

Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: quality assurance on behalf of SIOPEN-R-NET.

Viprey VF, Corrias MV, Kagedal B, Oltra S, Swerts K, Vicha A, Ladenstein R, Burchill SA. Viprey VF, et al. Among authors: kagedal b. Eur J Cancer. 2007 Jan;43(2):341-50. doi: 10.1016/j.ejca.2006.08.007. Epub 2006 Oct 4. Eur J Cancer. 2007. PMID: 17023157

7

Quantitative analysis of tyrosinase transcripts in blood.

Johansson M, Pisa EK, Törmänen V, Arstrand K, Kågedal B. Johansson M, et al. Among authors: kagedal b. Clin Chem. 2000 Jul;46(7):921-7. Clin Chem. 2000. PMID: 10894834

8

How useful are housekeeping genes? Variable expression in melanoma metastases.

Kågedal B, Farnebäck M, Håkansson A, Gustafsson B, Håkansson L. Kågedal B, et al. Clin Chem Lab Med. 2007;45(11):1481-7. doi: 10.1515/CCLM.2007.303. Clin Chem Lab Med. 2007. PMID: 17892440

9

Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo.

Johnsen JI, Segerström L, Orrego A, Elfman L, Henriksson M, Kågedal B, Eksborg S, Sveinbjörnsson B, Kogner P. Johnsen JI, et al. Among authors: kagedal b. Oncogene. 2008 May 1;27(20):2910-22. doi: 10.1038/sj.onc.1210938. Epub 2007 Nov 19. Oncogene. 2008. PMID: 18026138

10

Comparison of immunocytochemistry, real-time quantitative RT-PCR and flow cytometry for detection of minimal residual disease in neuroblastoma.

Ifversen MR, Kågedal B, Christensen LD, Rechnitzer C, Petersen BL, Heilmann C. Ifversen MR, et al. Among authors: kagedal b. Int J Oncol. 2005 Jul;27(1):121-9. Int J Oncol. 2005. PMID: 15942651

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

164 results

Search Page

Filters